$TEM

Tempus AI, Inc. Stock 12‑Month Price Target Cut to $62.21, Implies 42% Upside

Analyst estimates cited by FactSet show Tempus AI, Inc. average 12-month price target cut to $62.21 from $63.07. The range is $35 to $100 per share, implying about 42% upside versus the Jul. 31 close. Consensus remains “Buy” with 10 Buys, 7 Holds, and 2 Sells among 19 analysts.

Original reporting
Published Aug 3, 2026, 11:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 5:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tempus AI, Inc. Stock 12‑Month Price Target Cut to $62.21, Implies 42% Upside — source image
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

Consensus price target declines slightly while the rating stays “Buy,” implying analysts still expect upside but with reduced valuation expectations.

02

Market read

This is primarily a sentiment/valuation update from analysts, not a new operational or financial disclosure.

03

What to watch

The article does not state which analysts changed their targets or the rationale, so traders cannot infer whether the cut reflects deteriorating fundamentals or just valuation recalibration.

Relevance 4/10Novelty 3/10Timing: as of the Aug. 3 article update to consensus price targets

Background

The piece summarizes FactSet-based analyst consensus price targets and ratings for Tempus AI.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI’s average analyst price target was cut from $63.07 to $62.21, with a wide $35 to $100 range.

Expected impact

Limited near-term impact; any move is likely sentiment-driven around analyst revisions rather than a new company catalyst.

Evidence & confidence

The only disclosed change is the consensus price target level and implied upside, with no earnings, guidance, or operational update.

Market effects

Minimal, since this is a single-name analyst target adjustment without sector-wide new data.

None indicated.

None indicated.

Counterpoint

A target cut can be offset by continued “Buy” consensus, so the market may treat it as noise unless accompanied by thesis changes.

Key entities

  • Tempus AI, Inc.

    Subject of the article; consensus price target cut to $62.21 with “Buy” rating unchanged.

Related articles

$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.